Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab versus placebo in symptomatic, histologically active eosinophilic esophagitis
NL-OMON58798Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Tezepelumab with Placebo (2 arms). Primary endpoints: Histologic response at Week 24 and Change in Dysphagia Symptom Questionnaire score at Week 24. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON58798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58798.